These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 597712)

  • 21. Urinary hydroxyproline excretion in carcinoma of the prostate. A comparison of 4 different modes of assessment and its role as a marker.
    Mundy AR
    Br J Urol; 1979 Dec; 51(6):570-4. PubMed ID: 534843
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The measurement of urinary amino-terminal telopeptides of type I collagen to monitor bone resorption in patients with primary hyperparathyroidism.
    Minisola S; Pacitti MT; Rosso R; Pellegrino C; Ombricolo E; Pisani D; Romagnoli E; Damiani C; Aliberti G; Scarda A; Mazzuoli SF
    J Endocrinol Invest; 1997 Oct; 20(9):559-65. PubMed ID: 9413811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton.
    Pelger RC; Hamdy NA; Zwinderman AH; Lycklama à Nijeholt AA; Papapoulos SE
    Bone; 1998 Apr; 22(4):403-8. PubMed ID: 9556142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Total urinary hydroxyproline excretion before and after hypophysectomy in patients with bone metastases from breast carcinoma.
    Ditzel J; Jordal R; Riskaer N
    Acta Endocrinol (Copenh); 1968 Nov; 59(3):353-61. PubMed ID: 5754976
    [No Abstract]   [Full Text] [Related]  

  • 25. Bone alkaline phosphatase isoenzyme and urinary hydroxyproline in healthy subjects, patients with osteolytic metastases, and patients with primary hyperparathyroidism.
    Stĕpán JJ; Mikulecký M; Bek V; Broulík P; Pacovský V
    Neoplasma; 1989; 36(4):495-501. PubMed ID: 2770935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urinary hydroxyproline excretion as a marker of osseous metastasis in carcinoma of the prostate.
    Mooppan MM; Wax SH; Kim H; Wang JC; Tobin MS
    J Urol; 1980 May; 123(5):694-6. PubMed ID: 7420557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Hydroxyproline in the diagnosis of bone metastases in breast cancer].
    Gasser AB; Depierre D; Alberto P; Courvoisier B
    Schweiz Med Wochenschr; 1977 Jul; 107(28):984-6. PubMed ID: 897640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
    Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
    Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The diagnostic value of radiological, nuclear medicine and biochemical methods for detection of bone metastases in carcinoma of the prostate (author's transl)].
    Rost A; Fiedler U; Marshall F; Koppenhagen K
    Radiologe; 1977 Jun; 17(6):249-55. PubMed ID: 887744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases.
    Petrioli R; Rossi S; Caniggia M; Pozzessere D; Messinese S; Sabatino M; Marsili S; Correale P; Salvestrini F; Manganelli A; Francini G
    Urology; 2004 Feb; 63(2):321-6. PubMed ID: 14972482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Early detection of bone metastases in carcinoma of the prostate using the gamma camera].
    Flores Corral N; Unda M; Jorge A; Arregui R; Prieto N
    Arch Esp Urol; 1985; 38(2):131-6. PubMed ID: 4026394
    [No Abstract]   [Full Text] [Related]  

  • 32. Hydroxyproline as a marker for following patients with metastatic prostate cancer.
    O'Brien WM; Lynch JH
    J Urol; 1988 Jan; 139(1):66-8. PubMed ID: 3121868
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Urinary hydroxyproline levels in patients with prostatic carcinoma.
    Erol D; Adalar N; Güvençli S; Simşek F
    Int Urol Nephrol; 1983; 15(3):267-70. PubMed ID: 6654633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hydroxyproline in the early diagnosis of bone metastases in prostatic cancer.
    Kontturi MJ; Sotaniemi EA; Larmi TK
    Scand J Urol Nephrol; 1974; 8(2):91-5. PubMed ID: 4366246
    [No Abstract]   [Full Text] [Related]  

  • 35. Urinary hydroxyproline, serum alkaline phosphatase, calcium and phosphorus in patients with bone neoplasms.
    Radom S; Zulawski M; Golebiowska D
    Pol Med J; 1972; 11(4):809-14. PubMed ID: 4342776
    [No Abstract]   [Full Text] [Related]  

  • 36. New diagnostic use of bone marrow acid and alkaline phosphatase.
    Yarrison G; Mertens BF; Mathies JC
    Am J Clin Pathol; 1976 Oct; 66(4):667-71. PubMed ID: 970368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer.
    Clarke NW; McClure J; George NJ
    Br J Urol; 1992 Jan; 69(1):64-70. PubMed ID: 1737255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of enzyme, clinical, radiographic, and radionuclide methods of detecting bone metastases from carcinoma of the prostate.
    Schaffer DL; Pendergrass HP
    Radiology; 1976 Nov; 121(2):431-4. PubMed ID: 981622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Total and regional bone mass and biochemical markers of bone remodeling in metastatic prostate cancer.
    Revilla M; Arribas I; Sanchez-Chapado M; Villa LF; Bethencourt F; Rico H
    Prostate; 1998 Jun; 35(4):243-7. PubMed ID: 9609546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Borderline-low serum thyrotropin level is correlated with increased fasting urinary hydroxyproline excretion.
    Krakauer JC; Kleerekoper M
    Arch Intern Med; 1992 Feb; 152(2):360-4. PubMed ID: 1739367
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.